Overview News & Events Press Releases Events & Presentations Analyst Coverage Stock Information Stock Quote & Chart Financials & Filings SEC Filings Corporate Governance Documents & Charters Management Board of Directors Committee Composition Resources Investor FAQs Email Alerts Contact IR Overview News & Events Press Releases Events & Presentations Analyst Coverage Stock Information Stock Quote & Chart Financials & Filings SEC Filings Corporate Governance Documents & Charters Management Board of Directors Committee Composition Resources Investor FAQs Email Alerts Contact IR Events & Presentations Presentation Invivyd Corporate Presentation November 2022 November 1, 2022 Past Events Jefferies London Healthcare Conference Nov 15, 2022 at 4:25 PM GMT Click here for webcast Q3 2022 Invivyd Earnings Conference Call Nov 10, 2022 at 4:30 PM EST Click here for webcast H.C. Wainwright 24th Annual Global Investment Conference Sep 13, 2022 Morgan Stanley 20th Annual Global Healthcare Conference Sep 12, 2022 at 2:50 PM EDT Click here for webcast ASM Microbe 2022 Jun 9 - Jun 13, 2022 Supporting Materials Results from the Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Adintrevimab (ADG20) in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP) 847.7 KB Adagio Therapeutics, Inc. 2022 Annual Meeting of Stockholders May 26, 2022 at 8:30 AM EDT ECCMID 2022 Apr 23 - Apr 26, 2022 Supporting Materials ADG20, a half-life–extended monoclonal antibody in development for the prevention and treatment of COVID-19, demonstrated broad in vitro neutralisation against SARS-CoV-2 variants 860.1 KB Population pharmacokinetics of ADG20, an extended–half-life monoclonal antibody being developed for the treatment and prevention of COVID-19 1.2 MB Adagio Therapeutics, Inc. at 40th Annual J.P. Morgan Healthcare Conference Jan 13, 2022 at 7:30 AM EST Supporting Materials Adagio Therapeutics, Inc. at 40th Annual J.P. Morgan Healthcare Conference Presentation 3.9 MB ISIRV-WHO Conference 2021 Oct 19 - Oct 21, 2021 Supporting Materials (130) Broad and Potent In Vitro Neutralization of SARS-CoV-2 Variants by ADG20, a Half-Life Extended Monoclonal Antibody in Development for the Prevention and Treatment of COVID-19 519.6 KB (131) Evaluating the Safety, Tolerability, and Pharmacokinetics of ADG20, a Half-Life–Extended Monoclonal Antibody (mAb) in Development for the Prevention and Treatment of COVID-19: a Preliminary Analysis of a Randomized Phase 1 Study 295.1 KB Infectious Disease Society of America’s IDWeek 2021 Sep 29, 2021 Supporting Materials (633) Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment 532.3 KB (1086) A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model that a priori Predicts Intramuscular (IM) Pharmacokinetics of ADG20: an Extended Half-life Monoclonal Antibody Being Developed for the Treatment an 1.7 MB (1089) Use of a Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Prevention of Coronavirus Disease (COV 1.4 MB (1088) A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment of Coronavirus Disease (COVID-19) 1.6 MB
Presentation Invivyd Corporate Presentation November 2022 November 1, 2022 Past Events Jefferies London Healthcare Conference Nov 15, 2022 at 4:25 PM GMT Click here for webcast Q3 2022 Invivyd Earnings Conference Call Nov 10, 2022 at 4:30 PM EST Click here for webcast H.C. Wainwright 24th Annual Global Investment Conference Sep 13, 2022 Morgan Stanley 20th Annual Global Healthcare Conference Sep 12, 2022 at 2:50 PM EDT Click here for webcast ASM Microbe 2022 Jun 9 - Jun 13, 2022 Supporting Materials Results from the Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Adintrevimab (ADG20) in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP) 847.7 KB Adagio Therapeutics, Inc. 2022 Annual Meeting of Stockholders May 26, 2022 at 8:30 AM EDT ECCMID 2022 Apr 23 - Apr 26, 2022 Supporting Materials ADG20, a half-life–extended monoclonal antibody in development for the prevention and treatment of COVID-19, demonstrated broad in vitro neutralisation against SARS-CoV-2 variants 860.1 KB Population pharmacokinetics of ADG20, an extended–half-life monoclonal antibody being developed for the treatment and prevention of COVID-19 1.2 MB Adagio Therapeutics, Inc. at 40th Annual J.P. Morgan Healthcare Conference Jan 13, 2022 at 7:30 AM EST Supporting Materials Adagio Therapeutics, Inc. at 40th Annual J.P. Morgan Healthcare Conference Presentation 3.9 MB ISIRV-WHO Conference 2021 Oct 19 - Oct 21, 2021 Supporting Materials (130) Broad and Potent In Vitro Neutralization of SARS-CoV-2 Variants by ADG20, a Half-Life Extended Monoclonal Antibody in Development for the Prevention and Treatment of COVID-19 519.6 KB (131) Evaluating the Safety, Tolerability, and Pharmacokinetics of ADG20, a Half-Life–Extended Monoclonal Antibody (mAb) in Development for the Prevention and Treatment of COVID-19: a Preliminary Analysis of a Randomized Phase 1 Study 295.1 KB Infectious Disease Society of America’s IDWeek 2021 Sep 29, 2021 Supporting Materials (633) Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment 532.3 KB (1086) A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model that a priori Predicts Intramuscular (IM) Pharmacokinetics of ADG20: an Extended Half-life Monoclonal Antibody Being Developed for the Treatment an 1.7 MB (1089) Use of a Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Prevention of Coronavirus Disease (COV 1.4 MB (1088) A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment of Coronavirus Disease (COVID-19) 1.6 MB
Morgan Stanley 20th Annual Global Healthcare Conference Sep 12, 2022 at 2:50 PM EDT Click here for webcast
ASM Microbe 2022 Jun 9 - Jun 13, 2022 Supporting Materials Results from the Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Adintrevimab (ADG20) in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP) 847.7 KB
Results from the Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Adintrevimab (ADG20) in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP) 847.7 KB
ECCMID 2022 Apr 23 - Apr 26, 2022 Supporting Materials ADG20, a half-life–extended monoclonal antibody in development for the prevention and treatment of COVID-19, demonstrated broad in vitro neutralisation against SARS-CoV-2 variants 860.1 KB Population pharmacokinetics of ADG20, an extended–half-life monoclonal antibody being developed for the treatment and prevention of COVID-19 1.2 MB
ADG20, a half-life–extended monoclonal antibody in development for the prevention and treatment of COVID-19, demonstrated broad in vitro neutralisation against SARS-CoV-2 variants 860.1 KB
Population pharmacokinetics of ADG20, an extended–half-life monoclonal antibody being developed for the treatment and prevention of COVID-19 1.2 MB
Adagio Therapeutics, Inc. at 40th Annual J.P. Morgan Healthcare Conference Jan 13, 2022 at 7:30 AM EST Supporting Materials Adagio Therapeutics, Inc. at 40th Annual J.P. Morgan Healthcare Conference Presentation 3.9 MB
ISIRV-WHO Conference 2021 Oct 19 - Oct 21, 2021 Supporting Materials (130) Broad and Potent In Vitro Neutralization of SARS-CoV-2 Variants by ADG20, a Half-Life Extended Monoclonal Antibody in Development for the Prevention and Treatment of COVID-19 519.6 KB (131) Evaluating the Safety, Tolerability, and Pharmacokinetics of ADG20, a Half-Life–Extended Monoclonal Antibody (mAb) in Development for the Prevention and Treatment of COVID-19: a Preliminary Analysis of a Randomized Phase 1 Study 295.1 KB
(130) Broad and Potent In Vitro Neutralization of SARS-CoV-2 Variants by ADG20, a Half-Life Extended Monoclonal Antibody in Development for the Prevention and Treatment of COVID-19 519.6 KB
(131) Evaluating the Safety, Tolerability, and Pharmacokinetics of ADG20, a Half-Life–Extended Monoclonal Antibody (mAb) in Development for the Prevention and Treatment of COVID-19: a Preliminary Analysis of a Randomized Phase 1 Study 295.1 KB
Infectious Disease Society of America’s IDWeek 2021 Sep 29, 2021 Supporting Materials (633) Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment 532.3 KB (1086) A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model that a priori Predicts Intramuscular (IM) Pharmacokinetics of ADG20: an Extended Half-life Monoclonal Antibody Being Developed for the Treatment an 1.7 MB (1089) Use of a Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Prevention of Coronavirus Disease (COV 1.4 MB (1088) A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment of Coronavirus Disease (COVID-19) 1.6 MB
(633) Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment 532.3 KB
(1086) A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model that a priori Predicts Intramuscular (IM) Pharmacokinetics of ADG20: an Extended Half-life Monoclonal Antibody Being Developed for the Treatment an 1.7 MB
(1089) Use of a Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Prevention of Coronavirus Disease (COV 1.4 MB
(1088) A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment of Coronavirus Disease (COVID-19) 1.6 MB
